363: What Vinay Prasad’s ouster means for biotech and the FDA
The Readout Loud
00:00
Shifting Dynamics at the FDA
This chapter examines the implications of Vinay Prasad's departure from the FDA, particularly in relation to the biopharmaceutical company Sarepta and the agency's regulatory environment. It highlights concerns over political pressures affecting the FDA's operations, the potential influence on drug approval processes, and the importance of maintaining regulatory integrity. The discussion also considers the future of the FDA amidst changes in leadership and its impact on public health and safety.
Transcript
Play full episode
